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A B S T R A C T  
Background: This article presents cost-effectiveness analyses
of the major diabetes interventions as formulated in the
revised Dutch guidelines for diabetes type 2 patients in
primary and secondary care. The analyses consider two
types of care: diabetes control and the treatment of com-
plications, each at current care level and according to the
guidelines. 
Methods: A validated probabilistic diabetes model
describes diabetes and its complications over a lifetime
in the Dutch population, computing quality-adjusted life
years and medical costs. Effectiveness data and costs of
diabetes interventions are from observational current
care studies and intensive care experiments. Lifetime
consequences of in total sixteen intervention mixes are
compared with a baseline glycaemic control of 10%
HBA1c. 
Results: The interventions may reduce the cumulative
incidence of blindness, lower-extremity amputation, and
end-stage renal disease by >70% in primary care and
>60% in secondary care. All primary care guidelines
together add 0.8 quality-adjusted life years per lifetime. 
Conclusion: In case of few resources, treating complications
according to guidelines yields the most health benefits.
Current care of diabetes complications is inefficient. If
there are sufficient resources, countries may implement
all guidelines, also on diabetes control, and improve
efficiency in diabetes care. 
I N T R O D U C T I O N
Ageing, lifestyle changes and improved case finding will
increase the number of diabetes type 2 patients in most
societies in the near future.1 In the Dutch population,
diabetes led to a loss of 87,000 disability-adjusted life
years in the year 1996, ranking 10th of all diseases.2
Diabetes contributes to the occurrence of cardiovascular
disease, loss of vision and blindness, kidney failure, dis-
orders of peripheral circulation and loss of sensitivity and
pain in the legs, both leading to lower extremity ulcers
and amputation. It is the largest cause of blindness in
developed countries. About 15% of the dialysis patients in
the Netherlands have diabetic nephropathy. In the United
States, probably due to less diabetes control, this is 30%.3
Lower extremity amputation (LEA) is about 15 times more
frequent among diabetes patients than in the general
population.4,5 Healthcare costs related to diabetes and its
complications are high in affluent societies and accounted
for 2.5% of medical expenditures in the Netherlands in
1996.6
Cost-effectiveness analyses of diabetes guidelines are
relevant for clinical and health policy reasons. Long-term
clinical follow-up studies have demonstrated that intensive
control of blood glucose is effective in reducing the risk of
severe diabetes complications.7 Health economic studies
have shown that intensive treatment might lead to lower
healthcare costs, especially through fewer institutional
episodes.8 Such studies typically report the costs and
effects of an intervention given an existing level of control
and treatment and hence are context-specific. It is in the
interest of health policymakers to have more general
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information on allocation options in diabetes care given
the various prevention and treatment options for com-
plications.9,10 The premise of such analyses is that, for
any given level of resources available, it is desirable to
maximise the total aggregate health benefits.11-13 A com-
parison of health effects and costs of optional intervention
mixes against a baseline care level facilitates priority setting
at varying resource levels. The efficiency of current inter-
ventions may be considered.13 In this article a low diabetes
control level of 10% glycosylated haemoglobin (HbA1c) is
taken as baseline.
In the Dutch setting, primary care physicians are the
gatekeepers for secondary care facilities. About 80% of
type 2 diabetes patients are treated in primary care and are
referred only temporarily for secondary care consultation,
for example for eye screening.14 Specialists in ambulatory
secondary settings only treat the more difficult cases.
Here we present analyses for combinations of various
intervention mixes as formulated in the Dutch guidelines
for diabetes type 2 care15-17 and report on the allocation
options at different resource levels. We consider two
sets of intervention mixes for diabetes patients: one for
those in primary care and one for those in secondary
care.
M E T H O D S  
We estimate health effects and medical costs of current
care and care according to guidelines in the two groups
compared with a baseline setting. We collected data on
current care and used data on two experimental guideline
settings.18,19 We first summarise the application of the
disease history model for diabetes. Then, we describe the
computations to arrive at validated baseline estimates.
Last, to obtain comparable cost-effectiveness results, we
give the details on the input values for the effectiveness and
costs for the two sets of, in total, eight possible intervention
mixes for each set.
Multi-state disease model
We modified a probabilistic Markov model to describe the
Dutch diabetes situation.20 It describes the disease history
of type 2 diabetes and calculates quality-adjusted life
years (QALYs) lived with diabetes and its complications,
as well as lifetime medical costs. We refer to the original
publication for detailed description. Figure 1 gives an
overview of the model. It computes the occurrence of the
mild and severe long-term diabetic complications and the
excess mortality due to diabetes. The model distinguishes
five health states for retinopathy, four for nephropathy and
three for neuropathy. Patients may progress from states
without specific complications, through less severe inter-
mediate stages, towards three severe diabetes complications,
leading to severe vision loss (<20/100), kidney failure or
lower extremity amputation. The intermediate retinopathy
states are background retinopathy, macula oedema and
proliferative retinopathy. For nephropathy these are micro-
albuminuria and gross proteinuria, leading to end-stage
renal disease (ESRD). The neuropathic complications are
leg and foot ulcers and LEA, as results from ‘diabetic foot’. 
The model describes cohorts of diagnosed diabetes patients.
They enter the model one by one through stratified random
sampling until a stabilisation of results occurs. It accounts
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Figure 1
Overview of groups of disease states in diabetes model and action effects of intervention mixes 
The actual number of possible disease states is higher; see text.20
for their age and sex distributions and the distribution of
their HbA1c levels (table 1). The complication probabilities
are specific for age, gender and diabetes duration. There
are two independent mortality risks. One accounts for
diabetes-specific mortality and the other for the excess
mortality. The latter includes the excess cardiovascular
mortality risk. Figure 1 indicates that progression towards
severe states depends on both the level of diabetes control
and the level of specific treatment during the less severe
intermediate stages.
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Table 1
Model input values for diabetes control and preventive treatment of complications by patient group characteristics, 
effectiveness and annualised medical costs (1996 €)17-19,21,22
LEVEL OF CARE
Input variables patients, Current primary Primary guidelines Current secondary Secondary guidelines
intervention effects and care care care care
medical costs (P1.CC + P2.CC) (P1.GC + P2.GC) (S1.CC + S2.CC) (S1.GC + S2.GC)
Patient characteristics
No. of patients in survey 1371 459 929 1029
Mean age (SD) 65.2 (11.7) 66.1 (12.5) 69.2 (11.5) 69.2 (11.5)
Gender distribution (% men) 49 39 43 41
Diabetes control (P1 and S1)
Effectiveness
Average HbA1c % (S.D.) 7.6 (1.5) 7.0 (1.3) 7.8 (1.5) 7.2 (1.3)
Proportion of patients <7.0% 0.44 0.54 0.25 0.35
Proportion of patients >8.5% 0.28 0.12 0.24 0.15
Proportion of insulin patients 0.04 0.16 0.74 0.85
Medical costs 
Visits to general practitioner 128 318 128 318
Visits to various diabetes specialists 144 120 212 298
Visits to diabetes nurses 63 218 109 218
Visits to paramedics 0 184 48 120
Oral drug, insulin; self-control 347 386 977 1937
Laboratory tests 40 187 40 271
Treatment less severe complications (P2 and S2)
Effectiveness (probability reduction)
Laser coagulation in ME, postponing 0.05 0.03 0.05 0.03
blindness/low vision
Laser coagulation in PDR, postponing 0.08 0.015 0.08 0.015
blindness/low vision
ACE inhibitors in gross albuminuria 0.08 0.05 0.27 0.05
Foot clinic treatment neuropathy 0.17 0.05 0.25 0.05
Medical costs 
Eye screening visit 27 55 27 55
Laser coagulation + follow-up 272
ACE inhibitors 0 5 0 5
Visits diabetic foot clinic 20 58 20 29
Treatment severe complications
Medical costs
Blindness 1200 2550 660 3200
End-stage renal disease* 46,700
Diabetic foot ulcer** 563
LEA event/amputation status 12,000/450
P = primary care, S = secondary care, 1 = diabetes control, 2 = care of complications, CC = current care, GC = guideline care, ME = macula oedema, 
PDR = proliferative diabetic retinopathy, LEA = lower extremity amputation. * Weighted average of haemodialysis, peritoneal dialysis, home dialysis and
transplantation, ** weighted average of ambulatory and in-hospital treatment.
Baseline estimates
We applied the disease model to compute a baseline
situation (table 1). HbA1c indicates the level of diabetes
control and it is directly related to the occurrence of
complicating events later in life.7,20 We used this observed
relation to simulate a situation of very low diabetes control.
We assumed a HbA1c level of 10% to estimate a baseline
incidence of severe complications as this was used in the
original model version. This level of control is similar to
the Dutch level of control observed about 15 years ago in
comparable groups of patients.23 The present average
control level is below 8% HbA1c. We did not alter the
baseline incidence figures for severe complications but
did use Dutch mortality risk estimates. We multiplied the
gender and age-specific national mortality figures for 1990
by the increased hazard ratios for Dutch diabetics. An
incidence-prevalence-mortality model, used to compute
consistent values for each of its three components, estimates
at a hazard ratio of 1.55 for mortality for diabetic men and
2.27 for women as compared with the general
population.24,25 The ESRD case fatality rates are also
based on national figures.3
Next, we validated model outputs, comparing model
output data with empirical data from other sources. The
model calculates a baseline life expectancy at age 65 for
nondiabetic men of 14.0 and women of 18.6 years. The
empirical figures are 14.1 and 18.6.25 Computed baseline
life expectancies for diabetic men and women are 11.3 and
14.9 years. These figures compare well with the (rough)
historical estimates of 11.4 and 15.2.26 We also compared
model outcomes with the national registry figures for dia-
betes as well as neuropathy and nephropathy complications.
This was not possible for retinopathy, due to lack of data.
We found only minor differences, which we explain by the
lack of an, increasing, incidence trend, underestimation in
the registries and varying diagnostic criteria. We concluded
that our model values are consistent with available
empirical national data on diabetes occurrence.6
Last, we introduced utility weights to adjust the computed
life years. We found a single weight of 0.75 for diabetes
with or without mild complications based in our EuroQol
survey.27 The utility weight for blindness/low vision is
0.69, for ESRD 0.61 and for LEA 0.59.3,20,28
Input data for two sets of intervention mixes 
We collected data for the two types of intervention sets
(diabetes control and treatment of complications) for each
of the two patient groups (table 1). The difference between
the primary and secondary care group is that in the latter
diabetes control is more difficult and severe complications
are more frequent. Both conditions are indications for a
referral according to the guidelines.16 Both types of inter-
vention are considered at two different levels of care i.e.
current care and care according to the revised guidelines.15,17
The guidelines for diabetes control aim at lower levels of
HbA1c and the guidelines for complications recommend
frequent screening and preventive treatment though laser
coagulation, ACE inhibitors and foot clinic visits. 
So, the first group consists of primary care patients
receiving current care interventions (P.CC) or receiving
intervention mixes according to guidelines (P.GC). The
second group consists of secondary care patients receiving
current level of specialist interventions (S.CC) or receiving
intervention mixes according to guidelines (S.GC). Each
of four different intervention mixes distinguishes two
components: diabetes control (P1 or S1) and treatment of
complications (P2 or S2). Table 1 lists the input values for
diabetes control and treatment of complications by patient
group and by level of care. This leads to two sets of four
single (P1, P2 or S1, S2) and four combined (P1 + P2 or
S1 + S2) mutually exclusive intervention options at current
and guideline care level. For instance, the single option
P1.CC means diabetes control as currently given and
there is no treatment of complications in primary care.
In total, we analyse sixteen of those options of diabetes
interventions (table 2 and 3).
Effectiveness diabetes control
Empirical data regarding the level of diabetes control in
current and guideline settings (P1.CC, P1.GC, S1.CC and
S1.GC) have been collected in three studies.18,19,21 The
HbA1c figures for primary care patients (P1.CC and
P1.GC) are based on a two-year follow-up of 459 patients
in 22 primary care practices.19 Effectiveness figures for
current secondary care patients are from a survey in ten
general hospitals among 929 patients.22 Accounting for
control effectiveness (versus trial efficacy) we entered
the observed distributions of all HbA1c values into the
probabilistic calculations instead of the observed means.
Table 1 shows the HbA1c fractions for those values >8.5%
and for those between 7.0 and 8.5%. It indicates, for
example, that in all four groups more than 10% of the
patients remain above the 8.5% HbA1c level.
The relationship between HbA1c level and progression to
diabetic complications is estimated by a function reported
earlier.20 It has been validated for the Netherlands3 and is
based on the formula ((HbA1c/10)ˆ
). The calculated fraction
is the reduction of the transition probabilities towards each
of the three complication categories. The -coefficients are
specific for each type of less severe complication.20 The
function shows diminishing returns when lowering HbA1c
level through more intensive diabetes control. The UKPDS
study has confirmed the degree of diminishing returns.30
Effectiveness preventive treatment of complications
The effectiveness figures for the treatment of retinopathy
and nephropathy are from experimental trials and have been
reported before.3,20 In macula oedema, laser coagulation
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Table 2
Lifetime cumulative incidence (%) of diabetes complications by intervention mix component
INTERVENTION MIX COMPONENT
TYPE OF COMPLICATION BASELINE PRIMARY CARE PATIENTS SECONDARY CARE PATIENTS
P1.CC P2.CC P1.GC P2.GC S1.CC S2.CC S1.GC S2.GC
Background retinopathy 73.6 17.9 69.7 8.4 68.9 32.2 70.3 24.8 71.7
Macular oedema 38.5 7.2 36.0 3.3 35.9 12.9 34.3 9.1 35.3
Proliferative retinopathy 8.7 1.2 8.6 0.5 9.4 1.0 7.1 0.3 5.2
Low vision/blindness 13.5 2.5 9.1 1.0 8.1 4.1 7.4 2.9 4.0
Microalbuminuria 36.4 15.2 30.5 12.0 30.1 22.9 33.6 19.5 30.6
Macroalbuminuria 25.2 4.4 20.0 1.7 19.8 5.6 22.2 2.3 21.4
ESRD 5.6 0.9 4.1 0.3 2.5 1.1 2.8 0.4 1.7
Neuropathy 19.7 6.3 17.6 3.3 17.3 8.8 18.1 6.5 19.7
Lower extremity amputation 7.7 2.1 5.7 1.2 4.0 3.0 5.3 2.2 2.9
P = primary care, S = secondary care, 1 = diabetes control, 2 = care of complications, CC = current care, GC = guideline care, ESRD = end-stage renal disease.
Table 3
QALYs lived and medical costs (1996 €) per average remaining diabetic lifetime for the two independent sets P and S of
intervention mixes, ordered by QALYs lived
INTERVENTION MIXES MODEL OUTPUTS COST-EFFECTIVENESS RESULTS
NO. SINGLE SET NO. COMBINED QALYs LIFETIME POINT EXPANSION PATH +
MIXES P AND S MIXES LIVED COSTS ESTIMATE CER STEPWISE CER
0 Baseline care 9.294 2626 Reference 0 No option
1 S2.CC 9.384 349 Most dominant 1 Reference
2 S1.CC 9.410 1403 Dominant 40,852
3 S2.GC 9.424 411 Dominant 2 1561
4 S1.GC + S2.CC 9.425 2642 123
5 S1.CC + S2.CC 9.427 1384 Dominant
6 S1.CC + S2.GC 9.433 1427 Dominant 104,691
7 S1.GC 9.442 2637 76
8 S1.GC + S2.GC 9.446 2699 485 103,549
9 P2.CC 9.689 3247 1575
10 P2.GC 9.695 1355 Dominant
17 P2.GC + S2.GC 9.784 1704 Dominant 3 3587
18 Ibid + S1.CC 9.833 2782 291 21,897
11 P1.CC 9.945 3189 866
12 P1.CC + P2.CC 9.963 3141 771
13 P1.CC + P2.GC 9.986 3811 1714
14 P1.GC + P2.CC 10.020 8099 7543
19 Ibid + P1.GC 10.225 8648 6469 15,738
20 Ibid + P1.GC + S1.CC 10.235 9665 7483 17,654
21 Ibid + P1.GC + S1.GC 10.248 10,937 8720 19,927
22 Ibid + P1.CC 10.115 4222 1945 4 7607
15 P1.GC 10.128 8078 6543
16 P1.GC + P2.GC 10.130 8238 6716
23 Ibid + P1.GC 10.225 8648 6469 5 40,153
24 Ibid + P1.GC + S1.CC 10.236 9665 7483 6 94,916
25 Ibid + P1.GC + S1.GC 10.249 10,937 8720 7 99,444
Each set includes eight mutual exclusive mixes. Mixes in bold indicate one optimal expansion path. In the last column the CERs are relevant to this expansion
path. Here, in each step, the preceding optimum mix is the reference intervention. QALYs = quality-adjusted life years, baseline care = exclusively treatment of
severe complications (see costs in table 1), SD = standard deviation, CER = cost-effectiveness ratio (Euros/QALY), P = primary care, S = secondary care, 
1 = diabetes control, 2 = care of complications, CC = current care, GC = guideline care.
slows progression to a vision <20% at a hazard ratio of
1.17. In proliferative retinopathy, the hazard ratio is 1.71.
Data on the effectiveness of the prevention and treatment of
diabetic foot are scarce, especially on lowering amputation
rates. The Saint Vincent declaration states a 50% reduction
as the attainable goal. A Dutch study and others report
some supportive evidence for this, relatively pessimistic,
estimate. We applied hazard ratio to the amputation
transition probability of 3.72 for primary care patients
and for 2.41 in secondary care patients. Table 1 lists the
resulting changes in probabilities. Unless stated otherwise,
we present these three types of specific preventive treatments
combined as one intervention mix. We distinguish one
for current care (P2.CC and S2.CC) and for guideline care
(P2.GC and S2.GC).
Healthcare costs by intervention mix
We collected data regarding healthcare utilisation from the
same three studies and did a large cross-sectional study of
primary care patients. This study reports the actual health
utilisation and costs from 29 general practices of 1371
primary care patients. Health utilisation estimates for
current secondary care are from a hospital survey.21 The
cost estimates for the implementation of guideline care are
from two experimental studies applying intensive treat-
ment protocols in primary and secondary care patients.18,19
Table 1 lists the cost input values for diabetes control and
treatment for four categories of patients (P.CC, P.GC,
S.CC, and S.GC). Medical costs of amputation, follow-up
after amputation, end-stage renal disease and blindness
are assumed the same in all four patient groups. The
calculated lifetime cost estimates do not include the
medical costs of nondiabetes-specific conditions. We
provide more cost details in the report.17
R E S U L T S
We computed lifetime health effects and medical costs for
the sixteen diabetes intervention mixes in the two sets.
One set includes all possible mutual exclusive intervention
mixes for primary care (P) and the other (S) includes all
possible mutual exclusive mixes for secondary care. We
first present the specific health effects for the eight single
components of the intervention mixes (P1, P2, S1, S2) for
current care and guideline care (CC and GC). Next, we
present effects and costs of the eight single components
and eight combined mixes for control and preventive
treatment (P1 + P2 en S1 + S2). This leads to results for
in total sixteen intervention mixes as listed in table 2.
Health effects
Table 2 shows the incidence of complications for patients
under the four intervention mixes (P.CC, P.GC, S.CC, and
S.GC). It compares the effects of each single component,
i.e. diabetes control (P1 or S1) and preventive treatment of
complications (P2 or S2) with the baseline estimates. The
first column gives the results of the baseline scenario.
Diabetes control reduces the incidence of all complications.
Once less severe complications occur, preventive treatment
reduces progression to severe complications. Some 74%
of type 2 diabetes patients developed background
retinopathy under the baseline scenario, whereas blindness
occurs in 13.5%. Under current level of control, this is
reduced by more than 75%. Implementation of control
guidelines among primary care patients reduces the
cumulative incidence of blindness by more than 90%,
whereas ESRD falls by 67% from 5.6% to less than 0.5%.
The cumulative incidence of diabetes-related amputations
decreases from 7.7% in the baseline to 2.1% in the current
primary care setting. Similar, less substantial declines take
place among the more complex patients in ambulatory
secondary care. Implementation of secondary care guide-
lines leads to a reduction of blindness by 29%, of ESRD
by 62%, and of LEAs by about 27%. 
Table 2 also shows that the incidence of these severe
complications results in more patients with less severe
complications in the case of blindness (P2.GC and
S2.GC) and amputations (S2.GC). This leads to a relative
increase in costs. Reductions due to specific single treat-
ments of complications (not listed) are substantial, but
lower. Patients in current care with higher initial HbA1c
levels benefit more from guideline control than those
with lower initial values of HbA1c. 
Costs-effectiveness of diabetes interventions 
Figure 2 and table 3 present the means of the computed
QALYs lived and the discounted additional lifetime costs
per average diabetes patient for the sixteen possible
combinations of the four intervention mixes (P.CC,
P.GC, S.CC, and S.GC). The standard deviations for the
QALYs lived vary between 5.04 and 6.01 years and for the
lifetime costs between € 3103 and € 8265. The calculated
baseline life expectancy is 9.29 QALYs (SD=5.3). The
SD value compares well with observed figures for the
unadjusted life expectancy (CBS, 1992). The large SDs for
lifetime costs are due to the large variation in remaining
life years lived and the less frequent occurrence of the
most costly complications. This reflects clinical reality in
the treatment of older individual patients: given the high
individual risks of dying from other causes, future health
benefits and medical costs are uncertain at the individual
level.
The higher costs of guideline control (table 1) and the
treatment costs of complications are partially offset by
reductions in the costs of severe complications, especially
by savings on the care of severe renal and lower extremity
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complications. All primary care guideline interventions
together (P1.GC + P2.GC) show the highest health yield
for a single intervention set: about 0.8 QALY per average
lifetime. As a single intervention, eye screening and laser
coagulation (not listed) fall within the same range of cost-
effectiveness. The cost-effectiveness ratios for current
treatment for renal and lower extremity complications
(not listed), as single interventions, are much higher. 
Diabetes control in secondary care patients is still more
costly per unit HbA1c reduction. This explains why primary
control is more cost-effective than specialist control. As the
current control level is already high in both primary and
secondary care, even tightened control shows increasing
costs and diminishing returns. 
The two guideline intervention mixes for complications
(P2.GC and S2.GC) are dominant compared with the
current care of complications (P2.CC and S2.CC).
Guideline treatment of complications (P2.GC and S2.GC)
is cost-effective for three reasons: the intervention costs
are low, the effects are immediate in a large majority of
patients, and the indicated patient subgroup is relatively
small. In diabetes control, annual costs are higher, health
gains occur later in life, and many patients need to be
treated to prevent relatively few, severe and costly com-
plications. Therefore, current control is less cost-effective
Niessen, et al. Health effects and costs of diabetes treatment.
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Figure 2
The cost-effectiveness plane: QALYs lived and lifetime medical cost (3% discounted) for each intervention mix, the base-
line value and combinations of P and S mixes
P = primary care, S = secondary care, 1 = diabetes control, 2 = care of complications, CC = current care, GC = guideline care, QALYs = quality-adjusted
life years.
than preventive treatment of complications. Intensive
control is even less cost-effective. 
Table 3 and figure 2 indicate one possible optimal resource
expansion option, namely how to prioritise implementation
of efficient diabetes care starting from a baseline level.
Here, one would start by choosing the most cost-effective
option at the lowest budget needed, followed by the next
cost-effective and so forth, until resources are exhausted.11
In table 3, only the relevant combinations of P and S are
listed (colum three, numbers 17-25). Other combinations
are possible but not relevant for the path. For the sets of
mutual inclusive interventions (P and S) the order would
be to start with the guidelines treatment for complications,
next to add primary control, and lastly to implement
intensive secondary control. The optimum expansion path
for all combinations of all possible P and S mixes starts
with S2.CC. This is the most efficient and least expensive
option: in other words, it gives most savings, compared
with baseline level (table 3). The specific implementation
steps would be to improve this to S2.GC, add P2.GC, add
P1.CC, improve this to P2.GC, and lastly to include the
remaining S2.GC option. At mid-range budgets also other,
single and combined, mixes are on other expansion fron-
tiers, for example adding S1.CC after the implementation
of P2.GC and S2.GC. S1.CC (figure 1) can be implemented
at much lower costs, but is three times less cost-efficient,
at € 21,897 per QALY. At higher budgets, health effects
and the absolute costs for secondary care patients are less
influential due to the relatively small size of this group.
Health gains in this group, although very inefficient
(figure 2), need few additional euros per average lifetime.
Many more expansion paths are possible if uncertainties
such as standard deviations of health effects and lifetime
costs are taken into account. In the uncertainty analysis
all these paths are considered together; however this did
not change the conclusions.29
D I S C U S S I O N
Our analyses show that the diabetes care guidelines are cost-
effective in reducing severe and expensive complications.
This reconfirms the results of other studies.3,8 They also show
that implementation of the guidelines for complications
both in primary and secondary care reduces the current
inefficiencies in diabetes care. In case of low available
resources, a combination with moderate diabetes control
(P1.CC) is a good option. Also while including uncertainties,
the mixes that include guideline treatment of complications
continue to be a likely optimum choice. At high resource
levels, all primary and secondary care guidelines are
relevant. The interventions in secondary care are cost
saving compared with baseline; those for primary control
cost about € 6000 to € 7000 per QALY gained. 
Cost-effectiveness methodology 
The inclusion of a baseline scenario as a reference level is
one way to operationalise the generalised cost-effectiveness
analysis (CEA) approach of the WHO.11,13 Our baseline
scenario represents the average low controlled diabetic
still receiving care for severe complications. Estimates for
this situation can be relatively well documented as the
relationship between HbA1c blood values and the occurrence
of complications is well established. However, the exact
natural history of diabetes, when no treatment at all is
given, remains unknown. 
The first advantage of our approach is the possibility to
assess the relative efficiency of the current mix of care.
For the Netherlands, data on the level of current diabetes
care have recently become available.22 The present study
shows that, due to undertreatment, current primary care
of complications is inefficient as more costs due to severe
complications can be prevented (table 3). In a direct, context-
defined, comparison of current care and guidelines care this
would show as cost savings such as those we demonstrated
elsewhere for diabetes nephropathy.3 The comparison
with a baseline level makes the information for health
policymakers more complete and indicates the level of
expenditures still needed. 
The second advantage is the possibility to consistently
compare intervention mixes for two (or more) different
subpopulations at different available budgets after choosing
the right denominator. The unit of analysis is the average
cost per diabetic lifetime. Given the small numbers of
patients, the provision of secondary care leads to low
average lifetime costs for all diabetics, in spite of high
individual costs and higher cost-effectiveness ratios. In
case of a low budget, preventive treatment of these
patients according to this analysis deserves priority. This
is only one way to define the optimum benefit given a
fixed health budget to spend for the diabetes population.
QALYs and costs for both groups of patients in our analysis
have the same weights and have the same denominator
(the average diabetic lifetime). Different health policy
criteria, such as equity considerations, might lead to 
different weights, for example priority to the more dis-
abled.31 In this case, the policymaker might choose one of
the less likely, nevertheless optimum, options. 
There is an indirect interdependence between the health
gain and costs due to diabetes control and due to the
specific treatment of mild complications. Both reduce
severe complications. In a sense, the diabetes health states
act as communicating vessels. Better control leads to fewer
patients needing preventive treatment of complications.
Absence of diabetes control leads to more patients with
complications. Treatment of complications in the absence
of control leads, on average, to more health gain and
higher costs. The disease history model accounts for this
interdependence. Table 2 illustrates these results in both
the single and combined scenarios. 
The baseline estimates are difficult to validate. It might be
possible to use a specific calendar as a reference situation,
computing ‘backwards’.3,22 We did this and presented
some historical evidence. Our baseline quality-adjusted
life expectancy of 9.3 QALYs due to low diabetes control is
probably an overestimation. At a mean 10% HbA1c level,
there will be loss of health due to direct metabolic com-
plications, leading to less QALYs and higher costs in the
baseline scenario. This would lead to more favourable
cost-effectiveness ratios for the intervention sets.
Certainly within limits, it does not make an essential 
difference which baseline is chosen as long as its health
effect values are substantially lower than the computed
gains for the actual interventions. 
Our main conclusions on the optimum mixes, however, are
based on the relative values for health benefits and costs of
the studied intervention mixes, starting with the optimum
choice at the lowest budget level. This does not change for
different baseline values, nor would the relative values for
the interventions change. A comparison with interventions
for other diseases to compute the net population benefit,
however, would mean that the baseline values need redefin-
ing to include the characteristics of the other patient (or
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population or high-risk) groups involved. Uncertainties in
other model input values, such as those for discounting,
utility weights or transition probabilities, do not change
the set of relative values substantially either.
C O N C L U S I O N
In case of low resource availability (<€ 300 per diabetes
lifetime), none of the diabetes mixes is a relevant policy
option. Highly likely optimal strategies in resource-poor
countries are the implementation of guideline treatment
of complications and primary diabetes control (P2.GC,
S2.GC, and P2.CC). Our study shows the most likely cost-
effective options. However, other allocation criteria will
influence the decision-making. 
In countries with high resources, priority should also be
given to the guideline treatment of complications as
current diabetes care shows inefficiencies. At a budget of
over € 12,000 per diabetes lifetime, one can afford the
implementation of all interventions, although at the
individual level uncertainties are high. 
The implementation results depend very much on the
strategies followed.32 Simply distributing guidelines seldom
leads to (cost)effective implementation.33,34 Other constraints
in a cost-effective implementation are an already high
existing level of control and the lack of sufficient
improvement in many diabetics. There are diminishing
returns in intensive diabetes control. Further selection of
high-risk subgroups, by age, sex, risk factor status and
HbA1c level, may lead to the identification of more specific,
targeted and cost-effective implementation strategies. For
this, it will be necessary to conduct wider-scale and more
targeted evaluations of impact and costs of different
implementation practices of diabetes guidelines. 
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